Olaparib

Overview

Olaparib is a potent oral PARP inhibitor with anti-tumor activity, specifically designed to exploit the DNA-repair pathway deficiencies in cancer cells. It is primarily used for the treatment of ovarian, breast, and certain other types of cancer linked to BRCA mutations.

API suppliers (3)

Suppliers of Olaparib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• HUADONG MEDICINE (XI'AN) BODYGUARD PHARMACEUTICAL CO LTD2 active DMF
• Cipla USA, Inc.USA1 active DMF
• Cipla USA, Inc.USA1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (2 approved US products), the latest listed US patent on Olaparib expires 24 Oct 2041 and exclusivity 7 May 2027. Generic API sourcing typically opens up once these lapse.

Therapeutic areas